NDAORALCAPSULEPriority Review
Approved
Aug 2025
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
Priority Review
MODEYSO (dordaviprone) by Chimerix is protease activators [moa]. Approved for protease activator [epc]. First approved in 2025.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MODEYSO (dordaviprone) is an oral protease activator capsule approved by the FDA on August 6, 2025, developed by Chimerix. It works by activating proteases to treat conditions indicated for protease activator therapy. The drug represents a novel mechanism within the protease activation space.
Growth10.4 years to LOE
As a newly launched product in growth phase with zero competitive pressure, MODEYSO offers expanding commercial opportunities with likely team growth in sales, marketing, and market access roles.
Mechanism of Action
Protease Activators
Pharmacologic Class:
Protease Activator
Indications (1)
Career Relevance
MODEYSO represents a rare opportunity to join a newly launched, first-in-class product with zero competition and a decade-long exclusivity window. Career growth is robust in commercial and medical affairs functions, with early-stage hiring likely to expand significantly as the product builds market share.
Brand Manager
Worked on MODEYSO at Chimerix? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.